ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1550	National Cancer Institute	Html	en	Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.	red blood cells 0.477588 Lymphocyte-depleted Hodgkin lymphoma 0.50617 cancer treatment 0.499962 malignant tumor cells 0.49761 body 0.493073 PDQ cancer information 0.490723 Non-Hodgkin Lymphoma Treatment 0.479804 clinical trial search 0.486742 white blood cells 0.496539 Low-risk childhood Hodgkin 0.469047 Intermediate-risk childhood Hodgkin 0.468746 clinical trials 0.681512 recurrent hodgkin lymphoma 0.512969 cancer information summary 0.473675 clinical trial 0.539017 -predominant childhood Hodgkin 0.466011 blood cells 0.515545 weight loss 0.482905 refractory Hodgkin lymphoma 0.492835 lymph nodes 0.518888 sclerosis Hodgkin lymphoma 0.505736 radiation therapy 0.568298 childhood hodgkin lymphoma 0.931364 lymph node groups 0.523619 Lymphocyte-rich classical Hodgkin 0.468116	treatment 0.589509 night sweats 0.484683 High-risk childhood Hodgkin 0.468559 Hodgkin Lymphoma Treatment 0.532549 classical childhood Hodgkin 0.485325 low-risk Hodgkin lymphoma 0.490968 recurrent childhood Hodgkin 0.483388 cancer cells 0.532494 cellularity Hodgkin lymphoma 0.506213 Untreated childhood Hodgkin 0.4689 lymphocyte-predominant Hodgkin lymphoma 0.506119 treatment clinical trials 0.466252 National Cancer Institute 0.485234 lymph vessels 0.466622 new treatment 0.477189 bone marrow 0.510269 PDQ summary 0.464519 hodgkin lymphoma 0.996696 cancer clinical trials 0.496286 classical hodgkin lymphoma 0.530289 swollen lymph nodes 0.502296 lymphocyte-predominant childhood Hodgkin 0.463387 cancer 0.737848 information 0.498307	CLICK HERE
1613	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	skin cancer 0.626682 silibinin 0.690395 Silybum marianum 0.601821 cell lines 0.721716 silybin 0.669258 cell growth 0.69811 prostate cancer cell 0.66523 silymarin treatment 0.604627 cancer cell growth 0.625622 body weight 0.623855 human prostate carcinoma 0.68146 cancer epithelial cells 0.601164 glioma cell lines 0.609591 isolated compound silymarin 0.617496 Cancer Res 0.643092 human liver cells 0.615903 prostate cancer cells 0.651126 prostate carcinoma cells 0.621206 liver 0.635065 patients 0.607034 effects 0.642741 mild laxative effect 0.607369 Clin Cancer Res 0.601341 effect 0.675634 flavonoid antioxidant silymarin 0.723144	cancer chemopreventive effects 0.614128 cancer cells MDA-MB 0.601463 et al. 0.630532 Biophys Res Commun 0.659514 human colorectal cancer 0.630373 flavonoid hepatoprotector silymarin 0.616137 cancer cells 0.687834 cancer cell lines 0.67658 Biochem Biophys Res 0.658799 PUBMED Abstract 0.644662 ovarian cancer cells 0.604482 Silymarin effects 0.60576 studies 0.607771 liver function tests 0.604338 breast cancer cell 0.607955 cancer cell lines. 0.620697 silymarin 0.927821 silymarin stimulates synthesis 0.619814 cell cycle 0.608497 Abstract 0.706375 prostate cancer 0.673752 cancer 0.736552 dietary silymarin 0.618331 milk thistle 0.829966	CLICK HERE
1890	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	estadio lllC 0.524041 siguientes procedimientos 0.510716 siguientes aspectos 0.534365 causa efectos 0.516747 estadio lllB 0.524512 estadio lllA 0.524967 rayos x 0.508877 causó hinchazón 0.508591 cuáles lesiones 0.508991 Breast Cancer Risk 0.519727 epidérmico humano tipo 0.51911 carcinoma lobulillar 0.618686 crecimiento llamada her2 0.513006 cuerpo llamada ecograma 0.530459 pared torácica.ampliar mastectomía 0.517551 siguientes estadios 0.514163 proteína tipo factor 0.510936 células madre 0.671831 estadio iv 0.594708 ganglio linfático centinela 0.990128 Oncotype DX 0.510563 estadio ib 0.547143 prueba ayuda 0.524997 enlace drugs approved 0.56421 estadio ia 0.546556	mama.ampliar cirugía 0.509968 CLIS.Ampliar Carcinoma lobulillar 0.520349 efectos tardíos 0.515275 proteína her2 0.510017 Características genéticas 0.510197 bulbos minúsculos 0.511767 Breast Cancer Treatment 0.519669 cuántos genes 0.511329 incisión separada.ampliar mastectomía 0.517497 estadio iiia 0.543785 antecedentes familiares 0.532316 cabo pruebas 0.51404 estadio iiic 0.596075 estadio llB 0.525023 estadio llA 0.525437 Gynecologic Cancers 0.511174 mama.ampliar mamografía 0.511179 proteína llamada mTOR 0.510238 Breast Cancer 0.623769 sección cáncer 0.744984 pequeñas llamadas lobulillos 0.518854 genes brca1 0.512161 siguientes pruebas 0.535819 siguientes sumarios 0.517679	CLICK HERE
3447	National Cancer Institute	Html	es	Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el cese de fumar.	inglés quitguide 0.387847 voluntarios sanos 0.399525 mejores formas 0.386123 siguientes afecciones 0.472657 tabaco causa 0.867887 siguientes productos 0.425294 menor cantidad 0.421673 largo plazo 0.418123 cuánto tiempo 0.427364 Salud Pública 0.42102 PDQ Consumo 0.504465 Lung Health Study 0.500728 inglés llamadas tratamiento 0.496113 National Cancer Institute 0.439195 Más personas 0.44409	siguientes riesgos 0.405102 Instituto Nacional 0.538387 Leucemia mieloide aguda 0.525345 importantes beneficios 0.399221 Physician Data Query 0.786005 Estados Unidos 0.979435 prevención revisa 0.406999 Internet www.espanol.smokefree.gov 0.394612 siguientes medidas 0.45081 siguientes recursos 0.434379 principal causa 0.695094 Public Health Service 0.49625 tabaco encendido 0.560371 Quit Smoking Today 0.481661 enfermedades respiratorias 0.409989	CLICK HERE
3516	National Cancer Institute	Html	en	Phases of Clinical Trials	Information about the phases of cancer clinical trials. If a new treatment is successful in one phase, it will proceed to further testing in the next phase.	phase 0.792058 new treatment 0.947877 trial phases 0.360482 current standard therapy 0.316008 new cancer treatments 0.34108	phase clinical trials 0.478655 early phases 0.271363 phases 0.375183 drug treatment trials 0.287914	CLICK HERE
15607	National Cancer Institute	Html	en	RAS Spokes/Funding	null	Target KRAS-driven Cancer 0.470287 Memorial Sloan Kettering 0.519803 postdoctoral fellowship awardees 0.536142 mutant KRAS genes 0.739519 Kettering Cancer Center 0.57102 cell lung cancers 0.454 KRAS-Dependent Synthetic Lethality 0.494023 synthetic lethalities 0.645951 Oncogenic KRAS Synthetic 0.736037 pancreatic cancer research 0.594341 colorectal cancer 0.483021 Stanford University School 0.433776 cancer patient-derived organoids 0.505737 Sloan Kettering Cancer 0.56303 patient-derived xenografts 0.489445 mutant KRAS 0.946717 pancreatic cancer community 0.516641 human lung cancers 0.451785 small molecule screens 0.437567 Pancreatic Cancer Action 0.760787 mouse models 0.516476 Cancer Research Center 0.504949 RAS team 0.447514 KRAS co-dependencies 0.626256	KRAS research 0.731632 cancer research 0.612188 pancreatic cancer 0.855519 RAS Initiative workshop 0.507302 KRAS Synthetic Lethal 0.86327 KRAS Mutant Lung 0.726016 common mutant KRAS 0.721287 activity-based proteomic screens 0.446336 Finding KRAS Vulnerabilities 0.720626 PanCan KRAS Postdoctoral 0.721221 Frederick National Laboratory 0.644503 Synthetic Lethal Interactors 0.486265 Synthetic Lethality Screens 0.508669 Mutant KRas-Dependent Cancers 0.505292 KRAS effector pathways 0.684876 Cancer Action Network 0.707609 Deaconess Medical Center 0.441844 KRAS effectors 0.653247 Synthetic Lethal Relationships 0.482397 RAS Initiative 0.631295 colorectal cancer cells 0.482928 function high-throughput screens 0.439806 different KRAS mutations 0.711715 Synthetic Lethality 0.582272	CLICK HERE
15662	National Cancer Institute	Html	en	Cancer Disparities	Basic information about cancer disparities in the U.S., factors that contribute to the disproportionate burden of cancer in some groups, and examples of disparities in incidence and mortality among certain populations.	bile duct cancer 0.529873 colorectal cancer deaths 0.551836 colorectal cancer screening 0.555974 racial/ethnic minority groups 0.531719 cancer disparities—in particular 0.523151 racial/ethnic groups 0.863683 behavioral risk factors 0.505154 triple-negative breast cancer 0.524689 colorectal cancer 0.712116 key cancer incidence 0.561455 Asian Pacific Islanders 0.491901 cancer types 0.491276 racial/ethnic differences 0.492357 aggressive prostate cancers 0.499019 population groups 0.55611 white women 0.564935 higher death rates 0.607232 cancer health disparities 0.660515 higher rates 0.558073 prostate cancers 0.505687 clinical trial participation 0.493429 mortality disparities 0.547391 quality health care 0.505421 U.S. racial/ethnic groups 0.529263 United States 0.628581	minority racial/ethnic groups 0.535197 African Americans 0.773054 certain groups 0.517997 dense urban neighborhoods 0.497746 African American men 0.689721 higher socioeconomic status 0.531761 cancer measures 0.502411 excessive alcohol intake 0.493381 higher cancer burden 0.573329 environmental risk factors 0.507025 health care 0.541481 African American women 0.787066 colorectal cancer incidence 0.649355 American Indians/Alaska Natives 0.584845 specific disparities 0.531133 medically underserved individuals 0.505673 effective health care 0.506095 breast cancer 0.54205 statewide colorectal cancer 0.547339 biological differences 0.594269 cancer disparities 0.882383 late-stage cancer 0.50232 prostate cancer 0.522723 cancer 0.915156	CLICK HERE
16636	National Cancer Institute	Html	en	Medicinal Mushrooms (PDQ®)–Patient Version	Expert-reviewed information summary about the use of medicinal mushrooms as a treatment for people with cancer.	cancer treatment 0.568036 chemotherapy 0.524006 PDQ cancer information 0.669265 lung cancer 0.653736 turkey tail 0.777237 reishi 0.530583 clinical trials 0.606551 U.S. Food 0.502811 cancer information summary 0.619393 alternative cancer therapies 0.507487 clinical trial 0.529456 colorectal cancer 0.606284 patients 0.718186 cancer patients 0.586364 gastric cancer patients 0.525923 PSK 0.651884 adjuvant therapy 0.587394 randomized clinical trial 0.511048 standard cancer treatments 0.505852 NCI PDQ cancer 0.523643 reishi mushrooms 0.522541 complementary therapies 0.52479 radiation therapy 0.555862 Therapies Editorial Board 0.505693	medicinal mushrooms 0.712501 Complementary Therapies Editorial 0.519822 Drug Administration 0.559401 Cancer Information Specialist 0.499441 Cancer Information Service 0.564175 advanced lung cancer 0.497196 standard cancer treatment 0.517619 dietary supplements 0.500703 National Cancer Institute 0.663466 long time 0.498745 alternative medicine 0.537174 lung cancer patients 0.520738 gastric cancer 0.558768 turkey tail mushrooms 0.548558 traditional Chinese medicine 0.562629 breast cancer 0.533457 health 0.507834 animal studies 0.621773 natural killer cells 0.503348 active compound PSK 0.527105 alternative therapies 0.524113 cancer information summaries 0.503919 comprehensive cancer information 0.503793 cancer 0.900533	CLICK HERE
16858	National Cancer Institute	Html	en	Monitoring Research Grant Awards	NCI grants management staff regularly monitor individual grants within each budget period and within the overall project period.	program director 0.901745 overall project period 0.737705 Comptroller General 0.577687 documents 0.447442 Grants management officer 0.721935 grants management specialist 0.810551 federal regulation 0.560169 HHS awarding agency 0.720873 NCI staff work 0.714177 assessment 0.459846 progress reports 0.591992 budget period 0.591377 review 0.454674 weaknesses 0.464168 grants management 0.917818 telephone numbers 0.566417 financial reports 0.599567 required retention period 0.705874 reasonable access 0.563534 grant awards 0.568767 responsible GMS 0.614785 award process 0.554431 approved project 0.590335 recipients 0.469243 recipient cash expenditure 0.886855	NCI grants management 0.812999 problems 0.44631 recipient institution 0.874163 United States 0.564008 records 0.447146 audit reports 0.592365 site visits 0.586368 scientific progress 0.547344 Inspector General 0.563508 mutually agreeable course 0.708418 recipient’s inability 0.723309 internal controls 0.570063 Expenditure patterns 0.599349 financial systems 0.589323 pass-through entity 0.56408 monitors individual grants 0.762977 applicant organization 0.594032 unrestricted access 0.5713 principal investigator 0.553317 financial management 0.584417 specific guidelines 0.567884 management systems 0.560429 economic policy 0.555241 grant expenditures 0.689873	CLICK HERE
17291	National Cancer Institute	Html	es	Uso de recursos fidedignos	Información para ayudarle al público a evaluar las fuentes y la credibilidad de la información de salud impresa o disponible en Internet.	información personal 0.935578 siguientes preguntas 0.82336 conocimientos del cáncer que 0.776836 Comisión Federal 0.674467	Clinical Oncology 0.664087 American Society 0.659703 numerosos sitios 0.822963 acepte recomendaciones 0.778707	CLICK HERE